Clinical proteomics-driven precision medicine for targeted cancer therapy: current overview and future perspectives. (2nd April 2016)

• Record Type: Journal Article
• Authors: Zhou, Li; Wang, Kui; Li, Qifu; Nice, Edouard C.; Zhang, Haiyuan; Huang, Canhua
• Is Part Of: Expert review of proteomics. Volume 13:Number 4(2016)
• Page Start: 367
• Page End: 381
• Publication Date: 2016-04-02
• Subjects: Clinical proteomics -- precision medicine -- cancer therapy -- mass spectrometry -- drug target identification; Proteins -- Biotechnology -- Periodicals; Proteomics -- Periodicals; 572.6
• DOI: 10.1586/14789450.2016.1159959
• Languages: English
• ISSNs: 1478-9450

Abstract

ABSTRACT: Cancer is a common disease that is a leading cause of death worldwide. Currently, early detection and novel therapeutic strategies are urgently needed for more effective management of cancer. Importantly, protein profiling using clinical proteomic strategies, with spectacular sensitivity and precision, offer excellent promise for the identification of potential biomarkers that would direct the development of targeted therapeutic anticancer drugs for precision medicine. In particular, clinical sample sources, including tumor tissues and body fluids (blood, feces, urine and saliva), have been widely investigated using modern high-throughput mass spectrometry-based proteomic approaches combined with bioinformatic analysis, to pursue the possibilities of precision medicine for targeted cancer therapy. Discussed in this review are the current advantages and limitations of clinical proteomics, the available strategies of clinical proteomics for the management of precision medicine, as well as the challenges and future perspectives of clinical proteomics-driven precision medicine for targeted cancer therapy.